Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sinopharm Group Co ( (HK:1099) ) has issued an update.
Sinopharm Group Co. Ltd. has announced an extraordinary general meeting scheduled for February 12, 2025, to consider the appointment of several directors to its Board. The meeting will address the appointments of Mr. Sun Jinglin as an executive director, and Mr. Hu Ligang, Mr. Zu Jing, and Mr. Xing Yonggang as non-executive directors, with the Board authorized to determine their respective remunerations. Shareholders are encouraged to participate in the decision-making process regarding these key leadership roles.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company specializes in distribution and retail of pharmaceutical and healthcare products, providing services primarily in China and conducting business in Hong Kong.
YTD Price Performance: -2.05%
Average Trading Volume: 842
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.19B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.
